New structural information about an enzyme target in cancer medicine could help the development of next generation inhibitors. The enzyme, called PARP1, senses DNA damage and sends a cellular signal to carry out repair. PARP1 activity is important to many cancer types, making it an attractive target for treatments.
Clinical studies have shown that PARP1 inhibitors can be used as antitumor treatments, working by disrupting DNA replication and repair to kill cancer cells. More recently, researchers have begun exploring whether PARP1 can also be used as a target in treatments for other diseases, including Alzheimer’s and Parkinson’s disease, where the reduction in PARP1 hyper-activity can help cells survive.
For the first time, researchers from the Université de Montréal and the Institute of Cancer Research in the UK have captured a “snapshot” of PARP1 in the active state that it adopts after detecting DNA damage. The X-ray diffraction data that yielded these insights was obtained using the CMCF beamline at the Canadian Light Source (CLS) at the University of Saskatchewan and the Advanced Light Source in the U.S.
The region of PARP1 that inhibitors attack is quite mobile, making it difficult to fully understand this moving target, said Dr. John Pascal, a professor with the Department of Biochemistry and Molecular Medicine at the Université de Montréal and a member of this research team.
Certain inhibitors engage the dynamic regions of PARP1 and can act like a wrench jammed into a wheel or like a doorstop under a door, effectively helping to lock PARP1 onto DNA damage, explained Pascal. “This mode of inhibition could enhance the mechanism of killing cancer cells.” In contrast, inhibitors that avoid the dynamic regions and lack the “doorstop” effect could be better suited for neurodegenerative diseases, where cell preservation is the goal rather than cell killing.
The team’s new research, published in the journal Molecular Cell, furthers our understanding of how these enzymes behave and paves the way for the next-generation of PARP1 inhibitors.
Rouleau-Turcotte, Élise, Dragomir B. Krastev, Stephen J. Pettitt, Christopher J. Lord, and John M. Pascal. "Captured snapshots of PARP1 in the active state reveal the mechanics of PARP1 allostery." Molecular Cell (2022). https://doi.org/10.1016/j.molcel.2022.06.011
The Canadian Light Source (CLS) is a national research facility of the University of Saskatchewan and one of the largest science projects in Canada’s history. More than 1,000 academic, government and industry scientists from around the world use the CLS every year in innovative health, agriculture, environment, and advanced materials research.
The Canada Foundation for Innovation, Natural Sciences and Engineering Research Council, Canadian Institutes of Health Research, the Government of Saskatchewan, and the University of Saskatchewan fund CLS operations.
Photos: Synchrotron | CMCF | Pascal, Rouleau-Turcotte
Media relations:
Greg Basky
Communications Coordinator
Canadian Light Source
306-657-3531
greg.basky@lightsource.ca